Dexcom Reports Third Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
DexCom (DXCM) PT Raised to $86 at Bernstein SocGen Group
October 25, 2024 6:25 AM EDTBernstein SocGen Group analyst Lee Hambright raised the price target on DexCom (NASDAQ: DXCM) to $86.00 (from $82.00) while maintaining a Market Perform rating.
The analyst comments "In-line quarter. Revenue grew 3% organic, landing at the high-end of the reduced guidance range that DXCM set on the Q2 call (1% to 3%). U.S. sales declined -2% organic,... More
BTIG Reiterates Buy Rating on DexCom (DXCM)
October 25, 2024 5:23 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $120.00 price target on DexCom (NASDAQ: DXCM).
The analyst comments "Dexcom reported $994.2M in Q3 revenue (+2% y/y rep., +3% y/y org.), $4M above the consensus estimate of $990M. Q3 adj. EPS was $0.45, two cents above consensus. DXCM missed Visible Alpha consensus' U.S. sales expectation by $19M, reporting $701.9M (-2% y/y) and beat by $22M on OUS sales of $292.3M (+12% y/y rep.). Despite the light U.S. result, management commentary was upbeat, highlighting a record level of new patient starts, progress and momentum on... More
